- Home
- SRG vs NMRA Comparison
SRG vs NMRA Comparison
Compare SRG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- NMRA
- Stock Information
- Founded
- SRG 2014
- NMRA 2019
- Country
- SRG United States
- NMRA United States
- Employees
- SRG N/A
- NMRA N/A
- Industry
- SRG Real Estate Investment Trusts
- NMRA
- Sector
- SRG Real Estate
- NMRA
- Exchange
- SRG Nasdaq
- NMRA Nasdaq
- Market Cap
- SRG 232.1M
- NMRA 268.5M
- IPO Year
- SRG 2015
- NMRA 2023
- Fundamental
- Price
- SRG N/A
- NMRA $1.92
- Analyst Decision
- SRG
- NMRA Hold
- Analyst Count
- SRG 0
- NMRA 8
- Target Price
- SRG N/A
- NMRA $5.83
- AVG Volume (30 Days)
- SRG 168.0K
- NMRA 479.2K
- Earning Date
- SRG 11-11-2025
- NMRA 11-11-2025
- Dividend Yield
- SRG N/A
- NMRA N/A
- EPS Growth
- SRG N/A
- NMRA N/A
- EPS
- SRG N/A
- NMRA N/A
- Revenue
- SRG $15,346,000.00
- NMRA N/A
- Revenue This Year
- SRG N/A
- NMRA N/A
- Revenue Next Year
- SRG N/A
- NMRA N/A
- P/E Ratio
- SRG N/A
- NMRA N/A
- Revenue Growth
- SRG N/A
- NMRA N/A
- 52 Week Low
- SRG $2.43
- NMRA $0.61
- 52 Week High
- SRG $4.72
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- SRG 62.73
- NMRA 60.65
- Support Level
- SRG $4.14
- NMRA $1.70
- Resistance Level
- SRG $4.38
- NMRA $1.93
- Average True Range (ATR)
- SRG 0.16
- NMRA 0.14
- MACD
- SRG -0.02
- NMRA 0.01
- Stochastic Oscillator
- SRG 72.50
- NMRA 87.04
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.